MRC1 and endometrial cancer: Gylling and colleagues reported that 100% of gastric cancers and more than 90% of colorectal cancers in MMR mutation carriers (>90% were carriers of MLH1 mutations) were MSI high compared to 63% of endometrial cancers and 25% of renal cancers[21].